Stereochemistry | RACEMIC |
Molecular Formula | C15H21NO4 |
Molecular Weight | 279.3315 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)COC1=C2C(=O)OCC2=CC=C1
InChI
InChIKey=NFXPPCYKSAAUMQ-UHFFFAOYSA-N
InChI=1S/C15H21NO4/c1-15(2,3)16-7-11(17)9-19-12-6-4-5-10-8-20-14(18)13(10)12/h4-6,11,16-17H,7-9H2,1-3H3
Molecular Formula | C15H21NO4 |
Molecular Weight | 279.3315 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Alfurolol is a beta-adrenergic blocker. It is non-selective blocking drug with both intrinsic sympathomimetic activity and weak membrane stabilizing activity. There is also evidence that, unlike other beta-blocking drugs, only extremely small amounts of alfurolol cross the blood-brain barrier: because of this property, it has very little effect on the CNS. Alfurolol consistently produced a reduction in exercise heart rate at all times during the seven-hour period of observation, and the reductions were significantly different from the corresponding values after placebo treatment. Alfurolol is active both on heart rate and systolic pressure.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|